Amgen AMGN Nplate — Total revenues

Other product segments

Similar metrics at other companies

PTH

PTHSNet product revenues — Total Revenue

$10.67M—

RYTMProduct revenue, net — Total revenues

$60.11M+59.4%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

ALN

ALNYNet product revenues — Total revenues

$1.17B+74.4%

GERNProduct revenue, net — Total revenues

$51.77M+31.3%

ESP

ESPRProduct sales, net — Total Revenues

$43.4M+24.3%

Questions, answered.

What is Amgen's nplate — total revenues?

Amgen (AMGN) reported nplate — total revenues of $412M in Q1 2026.

How has Amgen's nplate — total revenues changed year-over-year?

Amgen's nplate — total revenues increased by 31.6% year-over-year, from $313M to $412M.

What is the long-term trend for Amgen's nplate — total revenues?

Over 4 years (2021 to 2025), Amgen's nplate — total revenues has grown at a 10.4% compound annual growth rate (CAGR), from $1.03B to $1.52B.

What does nplate — total revenues mean?

This metric represents the total gross sales generated from the Nplate product line, a therapeutic agent used for the treatment of chronic immune thrombocytopenia. It reflects the market demand, pricing power, and clinical adoption of this specific hematology asset within the company's broader portfolio. Monitoring this revenue stream helps assess the product's lifecycle stage and its contribution to the company's overall biotechnology therapeutic revenue.